Humanigen Inc (fka HGENQ)

[Fress]

Short % of Float (Apr 15, 2021) 42.27% Game stop short squeeze in the making book it!



Lenzilumab improved the relative likelihood of survival without need for invasive mechanical ventilation (IMV) by 54%, achieving the primary endpoint of the Phase 3 study

Clinical improvement was observed over and above other treatments, including steroids and/or remdesivir

Zuma-19 showing 100% ORR. People are sleeping on their Car-T technology.


$HGEN